High *MTHFR* promoter methylation levels in men confer protection against ischemic stroke

Shan Xu^{1#}, Qianping Shi^{2#}, Bo Li¹, Liyuan Han³, Guodong Xu⁴, Xiaolin Peng¹, Hongen Chen¹, Shuhong Dai¹, Wancheng Ma⁵, Changyi Wang^{1*}, Jianping Ma^{1*}

ABSTRACT

The *MTHFR* gene encodes methylenetetrahydrofolate reductase required for the metabolism of homocysteine (Hcy) – a previously reported independent risk factor for ischemic stroke (IS). In this study, we first aimed to clarify the association between DNA methylation levels in the *MTHFR* promoter and the risk of IS, followed by the analysis of potential interactions between environmental factors and DNA methylation levels that affect IS risk. We recruited 164 patients with hypertension and IS (case group) and 345 age-matched and sex-matched patients with hypertension only (control group). Demographic and clinical information was obtained using questionnaires, and blood samples were collected for biochemical analyses. Fluorescence quantitative methylation-specific PCR (qMSP) was used to detect *MTHFR* promoter methylation levels. A logistic regression analysis was performed to determine the relationship between environmental factors, *MTHFR* promoter methylation levels can predict IS. The mean *MTHFR* methylation levels in the case group (8.10 ± 6.14) were significantly lower than those in the control group (17.44 ± 3.16; *p* < 0.05). *MTHFR* promoter methylation levels were also lower in patients with plasma Hcy levels ≥15 µmol/L (10.65 ± 4.05) than in those with Hcy levels <15 µmol/L (16.74 ± 4.26, *p* < 0.001). Further, sex and *MTHFR* promoter methylation levels exhibited a preliminary interaction effect on IS risk. These results indicate that *MTHFR* promoter methylation status might have diagnostic value in IS.

KEYWORDS: Ischemic stroke; MTHFR; methylation; Hcy; hypertension

INTRODUCTION

Stroke is the second leading cause of death and longterm disability worldwide [1,2]. Ischemic stroke (IS) is the most common stroke subtype and accounts for an estimated 63–84% of all stroke cases [3]. IS is a multi-pathogenic disease driven by an interaction between environmental and genetic factors [4]. DNA methylation is an epigenetic, hereditary and reversible process, in which methyl groups are added to CpG islands [5]. This addition affects protein binding by altering the spatial configuration of DNA sequences [6]. DNA methylation constitutes an epigenetic

*These authors equally contributed

Submitted: 04 February 2020/ Accepted: 29 April 2020

Conflict of interest statement: The authors declare no conflict of interests

©The Author(s) (2020). This work is licensed under a Creative Commons Attribution 4.0 International License response to environmental factors and is thus considered to function as a molecular bridge between the environment and gene and protein expression [7]. The differential DNA methylation that occurs under different environmental conditions and the subsequent impact on chromatin structure has broad effects on gene expression [8]. Such epigenetic changes have an important role in mediating disease susceptibility [9]. Indeed, studies have shown that abnormal DNA methylation is associated with atherosclerosis [10], hypertension [11], coronary heart disease [12], and stroke [13] risk.

Our previous prospective cohort study found a positive association between hyperhomocysteinemia (HHcy) and IS in a cohort of 5488 patients with hypertension [14,15]. Another study confirmed that patients with hypertension and comorbid HHcy had a >12-fold increased risk of stroke [16]. Homocysteine (Hcy) is a sulfur-containing, non-proteinogenic amino acid that occurs naturally in the plasma [17]. Methylenetetrahydrofolate reductase (MTHFR) is an essential enzyme involved in Hcy metabolism. Genetic mutation of *MTHFR* can cause Hcy deficiency, while a decrease in its activity can lead to increased plasma Hcy levels and HHcy [18,19]. A polymorphism in *MTHFR* is strongly associated with IS [20,21]. We thus aimed to investigate whether *MTHFR* promoter methylation is associated with IS.

¹Nanshan Center for Chronic Disease Control, Shenzhen, China ²Department of Preventive Medicine, Shantou University Medical College, Shantou, Guangdong, China

³Department of Preventive Medicine, School of Medicine, Ningbo University, Ningbo, China

⁴Medical Record Statistics Room, Ningbo Medical Center Lihuili Hospital, Ningbo, China

⁵Luohu Center for Chronic Disease Control, Shenzhen, China

^{*}Corresponding authors: Changyi Wang and Jianping Ma, Nanshan Center for Chronic Disease Control, 5 Huaming Road, Shenzhen, China. E-mail: wangchangyi2002@163.com 710321019@qq.com

DOI: https://dx.doi.org/10.17305/bjbms.2020.4636

MATERIALS AND METHODS

Study design and participant recruitment

We recruited 164 patients with both hypertension and IS (case group) and 345 age-matched and sex-matched patients with hypertension only (control group), all from the Nanshan District Community Health Service Center in Shenzhen, China. A diagnosis of IS was confirmed by examination of medical records including reports of symptoms and examination results. The examinations included computed tomography (CT), magnetic resonance imaging (MRI), cerebral angiography, and transcranial Doppler ultrasound, in agreement with the World Health Organization (WHO) criteria, and were conducted by two cerebrovascular experts. Events were also diagnosed as IS if the scan did not visualize an infarction or hemorrhage, but the patient had symptoms that met the WHO criteria for IS.

The inclusion criteria were as follows: 1) patients who were aged ≥ 20 years and exhibited hypertension, 2) patients who had resided in Shenzhen for >6 months and could ensure their availability for follow-up analyses for at least 3 years, and 3) patients whose health and hypertension records were established in community health service centers. Exclusion criteria were as follows: 1) patients with secondary hypertension, cancer, severe liver, or kidney disease; 2) patients who were pregnant; 3) patients who were taking folic acid or vitamin B6 or B12; and 4) patients who were hypertensive and had a history of stroke or coronary heart disease. A diagnosis of IS was confirmed based on the results of pre-admission symptoms, CT, cranial MRI, cerebral angiography, and transcranial Doppler ultrasound images. All of the patients were informed of the study aims and the analyses that would be performed, and they provided written informed consent before the study started. This study was approved by the Ethics Committee of Nanshan Chronic Disease Prevention Center (approval ID: 1120170008).

Blood sampling and DNA extraction

CpG islands in the *MTHFR* promoter region were located using the UCSC genome browser. Specific primers to amplify the region by quantitative methylation-specific PCR (qMSP) were then designed using PyroMark Assay Design Software 2.0 (Table 1). After 12 hours of fasting, 5 mL venous blood was

TABLE 1. Pyrophosphate sequencing primers for CpG islands

 in the promoter region of *MTHFR* gene

Group	DNA sequence			
Forward primer	5' -AAAATTAGGTTTGGGGATTGTATAAGG-3'			
Reverse primer	5′-Biotin-CCAAATCATAACTTCACCATAACCA AATAAAC-3′			
Sequencing primer	5'-TTTTAGGAGGAGGTTAATTATAATG-3'			

MTHFR: Methylenetetrahydrofolate reductase

collected by venipuncture from each of the study participants into an ethylenediaminetetraacetic acid (EDTA) anticoagulant tube and immediately transported on ice to the laboratory for follow-up analyses or preservation at -80°C. DNA from each blood sample was extracted using a Lab-Aid 820 Nucleic Acid Extraction System (Xiamen Zhishan Biotechnology Co., Ltd.). The DNA concentrations and purities were measured on a NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific Corporation, USA).

Methylation analysis

DNA bisulfate conversion was achieved using an EZ DNA Methylation-Gold Kit (Zymo Research Corporation, USA), according to the manufacturer's instructions. The MTHFR promoter methylation status was then detected by qMSP [22]. The qMSP reaction consisted of 1.5 µL bisulfate-converted DNA, 0.5 µL forward primer, 0.5 µL reverse primer, 10 µL Zymo TaqTM PreMix, and 7.5 µL DNase-free and RNase-free water. The PCR cycling conditions were as follows: pre-denaturation at 95°C for 10 minutes, denaturation at 95°C for 20 seconds, 45 cycles of annealing at 56-58°C for 45 seconds, and an extension at 72°C for 20 seconds, final extension at 40°C for 5 minutes, and preservation at 4°C. After PCR amplification, the methylation level was detected on a Qsep100 DNA Analyzer (BiOptic Inc., China). The percentage of methylated reference (PMR) was used to quantify the methylation level [22]. The PMR value was obtained as previously described [22] by converting the PCR cycle threshold (Ct) value, as follows: PMR = 2-(Ct sample - Ct internal reference) × 100%.

Questionnaire-based data collection and physical measurements

Questionnaires and physical measurements were used to collect information on various environmental factors. The questionnaire collected information on the cohort demographics (including name, sex, birth date, nationality, occupation, education level, and marital status), health-related behaviors, dietary and emotional status, history of illness, and history of drug use. A questionnaire for dietary frequency was used to collect information on the consumption of foods rich in folic acid and vitamins, such as coarse grains, vegetables, and fruits. The Zung self-rating depression scale (SDS) [23] was used to evaluate the participants' emotional status. Here, emotional status is based on the answers given to 20 questions; each question is scored on a scale from 1 to 4. The maximum total score is 100: the lower the score, the better the emotional state. The upper limit of a normal score is 49 and participants with an SDS standard score ≥50 were considered to exhibit depressive symptoms. The physical measurements included height, weight, waist circumference, hip circumference, and blood pressure.

Biochemical analyses

The blood samples were analyzed for fasting blood glucose (Glu), total cholesterol (TC), low-density lipoprotein (LDL) cholesterol, triglyceride (TG), uric acid, creatinine, and plasma Hcy levels. An automatic biochemical analyzer (HITACHI 7080, Japan) was used to detect these blood biochemical indexes.

Statistical analysis

The qualitative data are presented as percentages (%) and a Chi-square test was used for statistical testing. The quantitative data are presented as means ± standard deviation, and a *t*-test was used to make comparisons between the groups. The methylation level of the *MTHFR* promoter region was divided into four quartiles (Q1, Q2, Q3, and Q4) and then analyzed by multivariate logistic regression analysis. An odds ratio (OR) with 95% confidence intervals (CIs) was used to express the correlation between the influencing factors and *MTHFR* methylation levels.

Logistic regression was used to construct three models: M1, M2, and M3. The fourth model, M0, did not correct for other factors. M1 corrected for age and gender. M2 corrected for smoking, body mass index (BMI), waist-hip ratio (WHR), depression, sleep, and oil and salt intake on the basis of M1. On the basis of M2, M3 corrected for factors such as systolic blood pressure (SBP), fasting Glu, TC, TG, LDL, and Hcy levels. Based on M3, the area under the receiver operating characteristic (ROC) curve was evaluated and used to determine the effect of the logistic regression model.

All of the statistical analyses were two-sided and a *p* value <0.05 was considered statistically significant. All of the statistical analyses were performed using IBM SPSS Statistics for Windows, Version 20.0. (IBM Corp., Armonk, NY, USA).

RESULTS

Hcy and *MTHFR* promoter methylation levels vary between cases and controls

We found significant differences in the *MTHFR* promoter methylation levels and Hcy status between the two groups. Specifically, the Hcy levels were $16.79 \pm 1.62 \mu mol/L$ in the case group and $15.06 \pm 1.45 \mu mol/L$ in the control group (p = 0.011). The *MTHFR* promoter methylation levels were also significantly lower in the case group (8.1 ± 6.14) than in the control group (17.44 ± 3.16 , p < 0.001; Table 2).

MTHFR promoter methylation levels vary with Hcy status

We found a significant difference in the *MTHFR* promoter methylation levels between the two groups in terms of the Hcy status (p < 0.001, Table 3). Specifically, the *MTHFR* promoter methylation levels were 16.74 \pm 4.26 in patients with an Hcy level <15 $\mu mol/L$ (group 1) and 10.65 \pm 4.05 in patients with an Hcy level >15 $\mu mol/L$ (group 2).

High *MTHFR* promoter methylation levels protect against IS

Univariate analysis showed that depression, alcohol consumption, and *MTHFR* promoter methylation levels influenced IS risk ($p \le 0.01$, Table 4). Multivariate analysis confirmed that depression, alcohol consumption, and *MTHFR* promoter methylation levels influenced IS risk (all $p \le 0.01$, Table 4).

High *MTHFR* promoter methylation levels confer protection against IS in men

We next constructed four models to analyze the relationship between IS and *MTHFR* promoter methylation levels by quartiles. After correcting for age, sex, smoking, BMI, WHR, depression, sleep, oil and salt intake, SBP, Glu, TC, TG, LDL and Hcy levels, we found that for the highest quartile of *MTHFR* promoter methylation level (Q4), the total OR (95% CI) of IS was 0.13 (0.07–0.24). The OR (95% CI) in men was 0.07 (0.02–0.16), which was lower than that in women (0.23 [0.09–0.54]). After correcting for the related factors in M2, the total OR (95% CI) was 0.14 (0.08–0.25) when compared with the lowest quartile (Q1). The protective effect in men (0.07 [0.03–0.16]) remained stronger than that in women after correction. After correcting for M3, the *MTHFR* promoter methylation levels in men had a statistically significant *p*-trend with IS (all *p* < 0.01; Table 5).

Interaction between sex and *MTHFR* promoter methylation levels affects IS risk

The interaction between sex and *MTHFR* promoter methylation levels was found to significantly affect IS risk (p = 0.011; Table 6). We found no interaction between age, depression, sleep, Hcy, Glu, and *MTHFR* promoter methylation levels in relation to IS risk (all p > 0.05).

MTHFR promoter methylation levels predict IS

To evaluate the predictive value of *MTHFR* promoter methylation levels on IS risk, we calculated the area under the ROC curve. We found that *MTHFR* promoter methylation levels could predict IS with ORs of 0.744 (95% CI: 0.702–0.786) at M0, 0.749 (95% CI: 0.712–0.797) at M1, 0.770 (95% CI: 0.749–0.832) at M2, and 0.776 (95% CI: 0.762–0.844) at M3, respectively (Figure 1).

DISCUSSION

In this study, we analyzed the correlation between *MTHFR* promoter methylation levels and IS risk, and the potential interactions between *MTHFR* promoter methylation

TABLE 2. Characteristics of 164 cases and 345 controls included in the stu	ıdy
--	-----

Characteristics	Control group (n=345) (%)/(Mean±SD)	Case group (n=164) (%)/(Mean± SD)	t/χ^2	<i>p</i> -value
Sex	~ ^	· ·	0.00	1.000
Male	179 (51.88)	85 (51.83)		
Female	166 (48.12)	79 (48.17)		
Age	66.62±9.36	66.23±8.99	0.46	0.646
Smoking	35 (10.14)	20 (12.20)	0.30	0.587
Passive smoking	66 (19.13)	27 (16.46)	0.37	0.545
Alcohol consumption	90 (26.09)	24 (14.63)	7.74	0.005
Oil intake, g/d			1.51	0.470
<25	69 (20.00)	33 (20.12)		
25-40	239 (69.28)	119 (72.56)		
>40	37 (10.72)	12 (7.32)		
Salt intake, g/d			5.08	0.079
≤6	84 (24.35)	50 (30.49)		
6-13	236 (68.41)	96 (58.54)		
>13	25 (7.25)	18 (10.98)		
Vegetable, g/d			0.08	0.963
<300	23 (6.67)	12 (7.32)		
300-500	228 (66.09)	108 (65.85)		
>500	94 (27.25)	44 (26.83)		
Sleep status			3.62	0.164
Bad	115 (33.33)	64 (39.02)		
Fairly good	157 (45.51)	60 (36.59)		
Good	73 (21.16)	40 (24.39)		
Depression	85 (24.64)	60 (36.59)	7.21	0.007
Glu, mmol/L	5.67±1.28	5.65±1.23	0.18	0.859
UA, μmol/L	358.43±94.62	358.18±89.31	0.03	0.977
TC, mmol/L	5.12±1.01	4.95±1.06	1.75	0.081
LDL, mmol/L	2.98±0.76	2.88±0.82	1.38	0.168
Waist, cm	87.25±9.09	87.01±10.31	0.26	0.797
Hip, cm	95.78±8.26	95.4±9.39	0.44	0.663
WHR	0.91±0.10	0.91 ± 0.09	-0.07	0.946
SBP, mmHg	133.95±16.52	134.64±15.59	-0.46	0.649
DBP, mmHg	82.5±11.14	81.93±11.06	0.55	0.586
BMI, kg/m2	24.41±2.93	24.33±2.89	0.29	0.773
TG, mmol/ L	$1.64{\pm}1.70$	1.59 ± 1.57	0.01	0.906
Hcy, μmol/L	15.06 ± 1.45	16.79±1.62	4.00	0.046
MTHFR	17.44±3.16	8.10±6.14	70.77	0.000

BMI: Body mass index; Glu: Glucose; UA: Uric acid; TC: Serum total cholesterol; LDL: Low-density lipoprotein; WHR: Waist-to-hip ratio; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; TG: Triglyceride; Hcy: Homocysteine; MTHFR: Methylenetetrahydrofolate reductase

Factor	n (%)	MTHFR methylation levels (Mean±SD)	F-value	<i>p</i> -value
Gender			0.11	0.746
Male	264 (51.87)	12.20±4.10		
Female	245 (48.13)	15.34±4.34		
Age, years			1.69	0.430
<60	90 (17.68)	12.61±3.65		
60-70	226 (44.4)	14.98±5.30		
≥70	193 (37.92)	12.64±3.33		
Smoking			0.11	0.744
No	454 (89.19)	13.90±4.05		
Yes	55 (10.81)	11.55±5.85		
Passive smoking			0.57	0.451
No	416 (81.73)	13.59±4.30		
Yes	93 (18.27)	13.75±3.95		
Oil intake, g/d			1.40	0.497
<25	102 (20.04)	13.60±3.52		
25-40	358 (70.33)	13.64±4.45		

Shan Xu, et al. A matched case-control study

TABLE 3. (Continued)

$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Factor	n (%)	MTHFR methylation levels (Mean±SD)	F-value	<i>p</i> -value
Shi hakagid4.580.101sé142 (6.33)14.69.1011s-1332 (66.23)14.39.3911s/343 (8.65)14.39.3911s/3035 (66.001)13.78.84.111s/500136 (60.01)13.78.84.111s/600136 (60.01)13.78.84.111s/600137 (64.11)13.89.50.801Sep statis28.80.280.28Goad127 (42.63)14.66.4.591Coad127 (42.63)14.66.4.591Coad132 (22.02)14.66.4.591Na354 (71.51)13.88.4.191Na354 (77.60)13.22.4.171Na354 (77.60)13.22.4.170.12Na353 (23.658)0.151Li523 (63.85)0.151UN_mod/L10.65-10511UN_mod/L10.900.86123.612.03.131124.6 (mak).339 (femak)32 (63.64)12.99.3.81123.612.03.1311123.612.03.1311123.612.03.1311123.612.03.1311123.612.03.1311124.613.26.1413.26.141123.612.03.1311124.613.26.1511124.613.26.15	>40	49 (9.63)	13.50±4.27		
-6-1134 (26.33)11.09-4.106-13323 (65.23)14.39-30113343 (84.5)14.38.760Vegetable of d35 (68.60)13.78-4.11300-50036 (66.01)13.78-4.11300-50013.8 (27.11)13.89-51.81Step status2.8 (27.13)13.89-51.81Step status2.8 (27.13)14.68-4.59Good1.17 (27.63)14.68-4.59Carrow3.0 (27.13)13.83-4.19Partices3.0 (27.13)13.83-4.19No3.4 (71.51)13.83-4.19No3.4 (71.51)13.83-4.19No3.5 (77.61)13.24-17No3.5 (77.61)13.24-17No3.5 (77.61)13.24-17No1.4 (22.49)16.74-4.26LP, mon/L1.0 (27.14)10.74-4.262.52.7 (54.42)16.74-4.262.52.7 (54.42)16.74-4.262.61.5 (28.05)1.5 (28.05)3.614.0 (73.7)2.36-162.52.7 (54.42)16.74-4.262.61.5 (28.05)1.5 (28.05)3.7 (56.15)2.9 (38.13)1.5 (28.13)3.8161.2 (23.7)1.5 (28.13)3.91 (mable)2.3 (36.14)1.5 (28.14)3.92 (mable)1.2 (23.71)1.5 (28.14)3.93 (mable)2.3 (36.18)1.5 (28.14)3.94 (mable)1.6 (28.12)1.5 (28.14)3.94 (mable)1.6 (28.12)1.5 (28.14)3.95 (mable)1.6 (28.12)1.5 (28.14)3.	Salt intake, g/d			4.58	0.101
n-1332 (85.3)1438.7.601334 (85.3)1438.7.60Vectable.gld1000.607-20035 (68.8)1137-8.4.11500128 (27.11)1378.4.13500128 (27.11)1378.4.26Seep stats28.30.243Goad17 (125.7)17.74.4.26Goad17 (125.7)17.74.4.26Seep stats8.40.202Code13 (22.0)1495.3.48Chross36 (7.76.0)13.28.4.10Na36 (7.76.0)13.22.4.17Na36 (7.76.0)13.22.4.17Na36 (7.76.0)15.10.4.4.5Alcohol commondor21.4 (5.76.8)Chross21.4 (5.76.8)13521.7 (54.2.8)14521.7 (54.2.9)14521.6 (5.6.8)14521.4 (5.76.8)146 (male). 339 (mmale)23.6 (3.6.8)146 (male). 339 (mmale)23.6 (3.6.8)146 (male). 339 (mmale)23.6 (3.6.8)147 (24.30)13.8 (4.6.5)147 (24.30)13.8 (4.6.5)148 (10.4).2.39 (10.4).121.4 (2.77.10.1)148 (10.4).2.39 (10.4).112.2 (2.77.10.1)149 (24.19.1)13.6 (3.6.1)141 (24.19.1)13.8 (4.6.1)149 (24.19.1)13.8 (4.6.1)141 (24.10.1)13.8 (4.6.1)141 (24.10.1)13.8 (4.6.1)141 (24.10.1)13.8 (4.6.1)141 (24.10.1)13.8 (4.6.1)141 (24.10.1)13.8 (4.6.1)141 (24.10.1)13.8 (4.6.1)	≤6	134 (26.33)	11.69±4.10		
i13i13(i)i13(k3)i13(k3)Vigenable. g/d35 (6.88)11.29-2.300.00"300-50035 (6.601)13.78-1.1113.89-5.101.8500138 (27.11)13.89-5.101.80.43Step stats28.013.78-1.1113.89-5.101.8Step stats19.0 (5.17)11.7.8.4.641.80.14Good13.12(2.3)14.684-459	6–13	332 (65.23)	14.39±3.91		
Naperal of the second	>13	43 (8.45)	14.38±7.60		
.ado356 (s8)11.29-230300-500336 (660)13724.115.60138 (27.11)13.89-508Step status2.830.243Bad179 (35.71)11.73.4.66Fairly good217 (22.03)14.68.4.59Good117 (22.03)14.68.4.59Good117 (22.03)14.68.4.59No36 (71.51)13.884.419No14 (32.49)13.02.4.55No395 (77.60)13.22.4.17No395 (77.60)13.22.4.17No395 (77.642)10.65.4.4.56No395 (77.642)10.65.4.4.56No20 (16.58)10.12.9.4.56No395 (77.64.2)10.66.4.3.67No36 (16.02.63)10.65.4.4.5UA, mod/L30.90.07-36.110.16.0.3.112.93.4.3.7-34.610.16.0.3.112.93.4.3.7-34.610.16.2.3.3.112.93.3.8-34.610.16.2.3.3.112.93.3.8-36.112.2.0.3.713.54.4.11-32.2.612.0.2.0.713.84.4.65-34.613.2.2.4.1313.54.4.13-34.613.2.2.4.1313.54.4.13-34.712.0.3.7813.54.4.13-34.613.2.2.4.1313.54.4.13-34.712.0.3.7813.54.4.13-34.613.2.2.4.1313.54.4.13-34.713.54.4.1313.54.4.13-34.613.2.4.2.513.54.4.13-34.713.54.4.1313.54.4.13-34.613.2.4.4.5	Vegetable, g/d			1.00	0.607
30038 (601)13 78+11>500138 (27.11)13 89±508243Skep sturs2830.243Bad77 (51.7)11.73+1260.243Bad217 (24.3)14.644-59366Cood113 (22.0)14.95±3.480.25Depression364 (71.51)13.84+19366No365 (75.0)13.22±4.1736Neasamption22.015.0±4.4536Pression365 (75.0)13.22±4.17300Neasamption12.22 (53.2)16.6±4.4536Pression22.0 (55.2)16.6±4.45361527.0 (54.2)16.6±6.367361527.0 (54.2)16.6±6.367361527.0 (54.2)16.6±6.3673736.1105 (20.63)16.6±3.673736.1105 (20.63)16.6±3.673737.416 (male). 339 (female)83.6±3.13737.416 (male). 339 (female)13.5±4.113737.22 (23.77)13.8±4.9538.436.112.2 (23.77)13.8±4.9537.123.230.0636.112.2 (23.77)13.8±4.9537.132.2 (33.13)13.2±3.4137.236.138.42.538.113.2±3.4132.4±3.339.112.2 (23.77)38.44.5539.139.139.134.113.2±3.4132.4±3.335.237.138.4±5.536.113.2 (23.73)39.137.23	<300	35 (6.88)	11.29±2.30		
>50018 (27.11)1289:508Skep stains28 (7) (35.17)11.73:4.26Bal17 (92.63)14.688.459Goad11.3 (22.03)14.688.459Depression0.8 (7) (20.8)0.8 (7) (20.8)No36 (7.15)13.004.450.8 (7) (20.8)Na145 (28.49)13.004.450.8 (7) (20.8)No36 (7.15)13.224.470.8 (7) (20.8)No95 (7.76)13.224.470.8 (7) (20.8)No95 (7.64)16.744.460.8 (7) (20.8)No20.2 (45.8)16.654.400.8 (7) (20.8)Alcha20.2 (45.8)16.654.400.8 (7) (20.8)Alcha105 (20.6)16.654.670.8 (7) (20.8)Alcha105 (20.6)16.654.730.8 (7) (20.8)Alf (mak)339 (femak)186 (65.4)12.99.3830.8 (7) (7) (7) (7) (7) (7) (7) (7) (7) (7)	300-500	336 (66.01)	13.78±4.11		
Slep statis2.830.243Bad19 (35.17)11.73.426Findy good217 (42.63)14.68.459Good13 (22.0)13.95.348Good13 (22.0)13.88.419Depression8.64 (71.51)13.88.419Yes145 (28.49)13.00.435Alcohd consumption2.300.129No35 (77.60)13.22.417Yes14 (22.0)15.04.45Hypurol/L16.74.4261.00.1471.522 (45.8)0.05.40.65LD, mod/L3.090.071-3.61105 (20.63)1.66.63.67LA, mod/L0.060.56.65CM, mod/L0.060.56.65CM, mod/L0.000.66.63.67CM, mod/L0.000.66.63.67CM, mod/L0.000.66.63.67CM, mod/L0.000.66.63.67CM, mod/L0.000.67.60CM, mod/L0.000.67.60CM, mod/L0.010.05.40.67-2.26132 (23.97)1.355.41.1-2.26132 (23.97)1.355.41.1-2.270.010.67.61-3.61123 (23.97)1.256.37.8-2.280.77.03)1.256.37.8-2.242.94.49.311.256.37.8-2.250.61.13.25.47.10.90-3.611.26.23.70.90-3.611.27.63.10.97.61-4.720.93.10.97.61-5.740.97.610.97.61-6.750.97.610.97.61<	>500	138 (27.11)	13.89±5.08		
İbd 179 (38.17) 11724-26 Farih good 217 (42.63) 14684-59 Good 113 (220) 14953.34 Depression 0.82 0.86 No 15 (28.49) 13004.45 12 Yes 145 (28.49) 13004.45 12 Alcoh cossumption 2.33 0.12 No 357.760 1322.417 12 Yes 141 (220) 15104.45 12 4001 Lycumol/L 15 22 (58) 0.05410 12 15 22 (58) 12934.37 12 36 OLA, mod/L 105 (20.63) 14004.417 12 36 416 (male), 433 (female) 13 (36.46) 14004.417 12 36 Cla, mod/L 0.06 367 12 32 36 416 (male), 433 (female) 13 (36.46) 14004.417 12 36 Cla, mod/L 12 (23.67) 13 38 4465 12 32 30 424 12 (13 (13 - 15	Sleep status			2.83	0.243
Early goad217 (42.6)14.68.4.59Goad13 (22.0)14.95.3.48Depression0.860.86No36 (4 (7.5))13.88.4.19Alcohol consumption2.300.129No35 (77.6)13.224.417No35 (77.6)13.224.417Yes14 (22.40)15.104.45Hig: punol/L12.23 (16.54.45)0.001-1522.0 (15.62)10.65.41.05LDL. mmol/L3.090.079-3.61105 (20.63)16.66.43.67LDL. mmol/L0.360.56.45UA, junol/L0.36 (36.46)12.99.483-416 (male), 439 (female)18.63.65.410.09-23637.76.0313.55.41.1-22612.29.713.84.4650.86-3.4112.29.713.84.4650.86-3.4112.29.113.854.510.86-3.422.29 (14.99)15.45.47.80.86-3.4313.29.43.113.264.370.37-3.442.29 (23.97)13.84.4650.87-3.4512.99.43.8113.264.370.86-3.4112.29.113.254.470.37-3.422.39 (18.11)13.264.370.36-3.4313.44.451.33.84.121.85-3.4413.29.45.131.941.94-3.4513.344.451.941.94-3.4513.344.451.941.94-3.4113.29.45.131.941.94-3.422.39 (18.13)1.32.54.17 <td>Bad</td> <td>179 (35.17)</td> <td>11.73±4.26</td> <td></td> <td></td>	Bad	179 (35.17)	11.73±4.26		
Goad113 (220)1495:348Depression0.820.366No364 (71.51)13884.419Yes145 (249)1322.4417No395 (77.60)1322.4417Yes147 (220)15.04.445Exy, and/L16.744.260.019 <td>Fairly good</td> <td>217 (42.63)</td> <td>14.68±4.59</td> <td></td> <td></td>	Fairly good	217 (42.63)	14.68±4.59		
Depression0.820.820.82No364 (71.51)13.884.19Yes145 (28.09)13.00.435Alcoh consumption2.300.129No395 (77.60)13.224.417Yes141 (22.40)15.10.445Rey molyL16.74.4260.001 <15	Good	113 (22.20)	14.95±3.48		
No364 (71.51)13.884.419Yes145 (28.49)13.004.435Alcohol consumption2.300.129No385 (77.60)13.224.17Yes14 (22.40)15.104.445Hey, Imol/L12.210.001<15	Depression			0.82	0.366
Yes16 (28.49)13.00:435Alcoho consumption2.300.12No395 (77.60)13.22:4.17Yes14 (22.40)15.10:4.45Hy; mol/L27 (54.42)16.74:4.26>1522 (45.8)10.65:4.05>LDL.mmol/L3.090.07-3.61404 (79.37)12.93:4.37-3.6110.5 (0.03)16.06:4.05UA,mmol/L0.360.05-3.6132.6 (63.64)12.99:3.83CTG, mmol/L0.000.060.34 - 2.26387 (76.03)13.55:4.11-2.2612.2 (3.37)1.35:4.11-2.26387 (76.03)13.55:4.11-2.26387 (76.03)1.35:4.11-2.26387 (76.03)1.35:4.11-2.270.030.68-6.13.72 (9.04)1.54:5.4.78-6.13.72 (9.04)1.34:4.65-6.23.611.22:6.3.79-7.442.94 (49.9)1.54:5.4.78-2.422.92 (43.81)1.32:6.1.7-2.422.92 (43.81)1.33:8.1.25-2.42.93 (43.61)1.33:8.1.25-2.42.94 (49.9)1.54:5.4.78-2.42.93 (43.81)1.32:4.13-2.42.94 (49.9)1.54:5.4.78-2.42.94 (49.9)1.54:5.4.78-2.42.94 (49.9)1.52:9.4.09-2.42.94 (49.9)1.52:9.4.09-2.42.94 (49.9)1.52:9.4.09-2.42.94 (49.9)1.52:9.4.02-2.42.94 (45.6) <t< td=""><td>No</td><td>364 (71.51)</td><td>13.88±4.19</td><td></td><td></td></t<>	No	364 (71.51)	13.88±4.19		
Alcohol consamption 230 0.19 No 395 (77.60) 13224.17 1 Yes 114 (240) 15.10.44.35 0.001 125 277 (54.42) 16.544.26 1 125 222 (55.8) 10.654.405 1 126 215 (50.63) 16.654.367 1 127. (54.42) 16.544.26 1 1 127. (54.42) 16.544.26 1 1 126. (50.63) 16.654.367 1 1 127. (54.42) 16.544.97 1 1 346 105 (20.63) 16.666.367 1 128.331 16.066.357 1 1 24.16 (male), 339 (female) 185 (85.4) 1.409.44.7 -416 (male), 339 (female) 185 (85.4) 1.299.33.3 129.42.26 12 (23.7) 13.54.11 22.26 12 (23.7) 13.54.16 22 (23.7) 13.54.415 1 24.16 (male), 23.39 (female) 13.26.378 1 25.26 12 (23.7) 15.45.478 24.28 22 (3.81) 13.26.478 24.29 14.96.49 13.26.478 24.24 22 (3.81) 13.26.478 26.2 48 (8.65.3) 14.29	Yes	145 (28.49)	13.00±4.35		
No 395 (77.60) 13.22.417 Yes 114 (22.40) 15.10-485 Hey mol/L I2.21 0.001 cl5 27.7 (54.42) 16.74±2.6 1 IDL 223 (45.88) 10.65±6.45 1 IDL 361 10.520.63 16.92±4.37 36.1 3.5.61 10.520.63 16.05±4.47 36.1 36.1 UA, mol/L 0.36 0.543 36.1 36.1 v416 (male)339 (female) 323 (63.46) 14.00±4.47 37.1 37.1 2.416 (male)339 (female) 323 (63.46) 12.029±3.33 36.1 36.1 2.416 (male)339 (female) 323 (63.46) 12.029±3.31 37.1 37.1 2.426 122 (23.07) 13.55±4.11 37.1 37.1 37.1 2.426 122 (23.97) 15.94±5.64 37.1 37.1 37.1 2.42 387 (76.03) 13.25±3.1 37.1 37.1 37.1 2.42 387 (76.03) 13.25±3.1 37.1 37.1	Alcohol consumption			2.30	0.129
Yes 14 (22.40) 1510:445 Hcy.mol/L I2.21 0.001 <15	No	395 (77.60)	13.22±4.17		
Hey µmol/L 12.1 -0.001 <15	Yes	114 (22.40)	15.10±4.45		
15 277 (54.42) 16.744.26 15 232 (45.8) 10.6524.05 LDL.mmol/L 309 0.079 3.361 105 (20.63) 16.662.367 105 (20.63) 10.652.053 2.361 105 (20.63) 16.662.367 105 (20.63) 0.548 < 416 (male). 339 (female) 132 (63.66) 12.992.383 105 (20.63) 0.548 < 416 (male). 339 (female) 186 (36.54) 12.992.383 100 (20.67) 0.967 0.34-226 132 (23.97) 13.844.465 103 (20.68) 0.868 < 61 122 (23.97) 13.844.465 103 (20.868) < 61 122 (23.97) 15.941.564 21.97 0.306 < 24 22.94 (33.81) 13.264.378 21.97 0.306 < 24 23.94 (33.84) 13.264.378 21.97 0.306 < 24 23.94 (33.84) 13.264.378 21.94 (38.95) 0.91 (3.94) < 24 23.94 (33.84) 13.264.378 21.94 (3.86) 0.805 < 24 23.94 (33.84) 13.264.378 21.94 (3.86) 0.805 < 120	Hcv. umol/L			12.21	< 0.001
15 23 (458) 10654405 LDL,mmol/L 3.09 0.079 3.61 404 (79.37) 12.93:43.7 3.64 405 (20.63) 16.66:3.67 10.23:43.7 UA, µmol/L 0.36 0.548 <416 (male), <339 (female)	<15	277 (54.42)	16.74±4.26		
LDL, mmol/L 3.09 0.079 3.61 404 (79.37) 12.93.4.37 3.92 0.079 3.61 404 (79.37) 12.93.4.37 3.09 0.079 3.61 105 (20.63) 16.663.367 3.09 0.079 3.61 105 (20.63) 14.00.4.437 3.09 0.079 3.61 (male), 3.39 (female) 3.87 (76.03) 13.553.411 3.09 0.09 2.03 3.87 (76.03) 13.553.411 3.09 0.08 3.61 122 (23.97) 13.843.465 3.09 0.08 3.61 122 (23.97) 15.945.564 3.09 0.08 3.61 122 (23.97) 15.945.564 3.09 0.07 0.794 3.61 122 (23.97) 15.945.564 3.09 0.06 3.06	>15	232 (45.58)	10.65+4.05		
3.61 404 (79.37) 12.93.437	LDL, mmol/L	(10100)		3.09	0.079
3.61 105 (20.63) 1666:367 UA, µmol/L 0.36 0.548 <416 (male), 339 (female) 323 (63.46) 14.004.447 12.993.83 TG, mmol/L 0.00 0.967 $0.34-226$ 387 (76.03) 13.554.11 12.226 226 122 (23.97) 13.844.465 12.226 6.1 387 (76.03) 12.964.381 12.964.381 < 6.1 387 (76.03) 12.964.381 12.964.381 < 6.1 387 (76.03) 12.964.381 12.964.381 < 6.1 2.23 (43.81) 13.264.378 12.924.381 $< 24-28$ 2.23 (43.81) 13.264.378 12.924.92 $24-28$ 2.23 (43.81) 13.264.378 12.924.92 $< 24-28$ 2.33 (8.646) 15.294.409 0.98 0.805 < 52 68 (13.66) 15.294.409 0.98 0.805 < 52 68 (13.66) 15.294.409 0.98 0.805 < 52 68 (13.66) 12.924.72 12.946.72 12.946.72 12.946.72 $210-140$ 2.97 (58.35) 14.284.339	<3.61	404 (79.37)	12.93+4.37		
LA, µmol/L 0.36 0.548 <416 (male), <339 (female)	>3.61	105 (20.63)	16.66+3.67		
r446 (male), ≥339 (female) 323 (63.46) 14.00±4.47	UA.umol/L)		0.36	0.548
110 100 0.00 0.967 0.34-2.26 387 (76.03) 13.55±4.11 122 2.26 122 (23.97) 13.84±4.65 0.00 0.868 <6.1	<416 (male), <339 (female)	323 (63 46)	14 00+4 47	0.00	0.010
TC, mm0/L 0.00 0.967 0.34-226 387 (76.03) 13.55 ±4.11 122 ±2.26 122 (23.97) 13.84 ±4.65 122 Glu, mm0/L 0.03 0.868 <6.1	>416 (male), >339 (female)	186 (36 54)	12 99+3 83		
1.01.00.11.01.00.10.00.1 $0.34-226$ 387 (76.03) 1355 ± 1.1 12 ≥ 226 122 (23.97) 1384 ± 65 0.030.868 < 6.1 387 (76.03) 1296 ± 3.81 1 ≥ 6.1 122 (23.97) 1594 ± 5.64 11BMI, kg/m²2.370.306 < 24 229 (44.99) 1545 ± 4.78 1 $24-28$ 223 (43.81) 1326 ± 3.78 11 ≥ 28 57 (11.20) 9.12 ± 3.61 11TC, mmol/L0.070.7944.62441 (86.64) 1338 ± 4.25 1 ≤ 62 68 (13.36) 1529 ± 4.09 0.80511SBP, mmHg0.980.805111 $2120-140$ 297 (58.35) 1612 ± 12.33 11 $140-160$ 129 (25.34) 1251 ± 4.05 11 ≥ 160 40 (7.86) 1052 ± 4.72 20.473 < 80 165 (32.42) 1230 ± 3.36 11 $< 90-100$ 80 (15.72) 1551 ± 3.12 11 ≥ 100 33 (648) 1184 ± 8.87 11 WHR 103 (20.24) 1166 ± 3.71 11 < 0.9 (make) 0.83 (female) 406 (79.76) $1417+36$ 1	TG mmol/L	100 (00.01)	12.572000	0.00	0.967
bbs bbs <td>0.34-2.26</td> <td>387 (76.03)</td> <td>13 55+4 11</td> <td>0.000</td> <td>01507</td>	0.34-2.26	387 (76.03)	13 55+4 11	0.000	01507
Lato 100 003 0868 6.1 387 (76.03) 12.96±3.81	>2.26	122 (23 97)	13 84+4 65		
Action (A1)387 (76.03)12.96±3.810.0000.000 ± 6.1 122 (23.97)15.94±5.6412.0112.92BMI, kg/m²2.370.306 $\angle 24$ 229 (44.99)15.45±4.7812.22 $24-28$ 223 (43.81)13.26±3.7812.92 ≥ 28 57 (11.20)9.12±3.6112.12TC, mmol/L0.070.794 $\leftarrow 6.2$ 441 (86.64)13.38±4.25 ≥ 6.2 68 (13.36)15.29±4.09SBP, mmHg0.980.805 < 120 43 (84.5)16.12±12.33120-1402.97 (58.35)14.28±3.39140-160129 (25.34)12.51±4.05 ≥ 160 40 (7.86)10.52±4.72DBP, mmHg2.510.473 < 80 165 (32.42)12.30±5.36 $80-90$ 231 (45.38)14.29±3.34 $90-100$ 80 (15.72)15.51±3.12 ≥ 100 33 (6.48)11.84±8.87WHR1.910.167 < 0.9 (male), 0.8 (female)400 (79.76) 406 (79.76)14.17±4.36	Glu. mmol/ L	122 (20077)		0.03	0.868
a.h.b.h.b.h.b.h. $s.h.$ 122 (237)15945.64BMI, kg/m²2.370.306 < 24 229 (44.99)15.45±4.78 $24-28$ 223 (43.81)13.26±3.78 ≥ 28 57 (11.20)9.12±3.61TC, mmol/L0.070.794 < 6.2 441 (86.64)13.38±4.25 ≥ 6.2 68 (13.36)15.29±4.09SBP, mmHg0.980.805<120	<61	387 (76.03)	12 96+3 81	0.00	0.000
LandLand2.370.306BMI, kg/m²2.29 (44.99)15.45±4.782.370.306 $24-28$ 223 (43.81)13.26±3.782.370.306 ≥ 28 57 (11.20)9.12±3.617070.794 < 6.2 441 (86.64)13.38±4.257070.794 < 6.2 68 (13.36)15.29±4.097080.805 < 528 68 (13.36)15.29±4.0970980.805 < 120 43 (8.45)16.12±12.3370980.805 < 120 43 (8.45)14.28±3.3970980.805 < 140 297 (58.35)14.28±3.397097098 < 140 129 (25.34)12.51±4.0570987098 < 140 165 (32.42)12.30±5.367097097 < 80 165 (32.42)12.30±5.367097098 $< 90 - 100$ 80 (15.72)15.51±3.127097097 < 100 33 (6.48)11.84±8.87709709 $< 0.9 (male), 0.8 (female)$ 103 (20.24)11.66±3.71709 $< 0.9 (male), 0.8 (female)$ 400 (79.60)14.17±4.36719	>61	122 (23 97)	15 94+5 64		
IntegralLastSaco 24 $229 (4.99)$ 1545 ± 4.78 326 ± 3.78 ≥ 28 $57 (11.20)$ 9.12 ± 3.61 70.794 < 6.2 $441 (86.64)$ 13.38 ± 4.25 326 ± 3.78 ≥ 6.2 $68 (13.36)$ 15.29 ± 4.09 80.805 < 52 $68 (13.36)$ 15.29 ± 4.09 80.805 < 120 $43 (845)$ 16.12 ± 12.33 80.805 < 120 $43 (845)$ 16.12 ± 12.33 $120-140$ $297 (58.35)$ 14.28 ± 3.39 $140-160$ $129 (25.34)$ 12.51 ± 4.05 2160 $40 (7.86)$ 10.52 ± 4.72 $BP,$ mmHg $231 (45.38)$ 14.29 ± 3.34 42.9 ± 3.34 42.9 ± 3.34 $90-100$ $80 (15.72)$ 15.51 ± 3.12 10.167 ≥ 100 $33 (648)$ 11.84 ± 8.87 $19.10 (1.67)$ WHR $103 (20.24)$ 11.66 ± 3.71 $19.10 (1.67)$ $< 0.9 (male), 0.8 (female)$ $406 (79.76)$ 14.17 ± 4.36 11.62 ± 3.71	$BMI_k k\sigma/m^2$	122 (20077)	10.7 1_0.0 1	2.37	0.306
24-28 223 (43.81) 13.26±3.78 ≥28 57 (1.20) 9.12±3.61 TC, mmol/L 0.07 0.794 <6.2	<24	229 (44 99)	15 45+4 78	2107	01000
11 B2 13 (11.20) 9.12±3.61 TC, mmol/L 0.07 0.794 <6.2	24-28	223 (43.81)	13 26+3 78		
TC, mol/L 0.07 0.794 <6.2	>28	57 (11.20)	912+361		
<6.2	TC. mmol/L	07 (11:20)	7112-0101	0.07	0.794
≥6.2 68 (13.36) 15.29±4.09 SBP, mmHg 0.98 0.805 <120	<62	441 (86 64)	13 38+4 25	0107	0
SBP, mmHg 0.98 0.805 <120	>6.2	68 (13.36)	15 29+4 09		
<120	SBP mmHg	00 (10.00)	10.27 - 1107	0.98	0.805
120-140 297 (58.35) 14.28±3.39 140-160 129 (25.34) 12.51±4.05 ≥160 40 (7.86) 10.52±4.72 DBP, mmHg 2.51 0.473 <80	<120	43 (8 45)	16 12+12 33	0.20	0.000
140-160129 (25.34)12.51 ±4.05 ≥ 160 40 (7.86)10.52 ±4.72DBP, mmHg2.510.473 < 80 165 (32.42)12.30 ± 5.36 $80-90$ 231 (45.38)14.29 ± 3.34 $90-100$ 80 (15.72)15.51 ± 3.12 ≥ 100 33 (6.48)11.84 ± 8.87WHR1.910.167 < 0.9 (male), 0.8 (female)103 (20.24)11.66 ± 3.71 ≥ 0.9 (male), 0.8 (female)406 (79.76)14.17 ± 4.36	120-140	297 (58 35)	14 28+3 39		
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	140-160	129 (25 34)	12 51+4 05		
DBP, mmHg 2.51 0.473 <80	>160	40 (7 86)	10 52+4 72		
<80	DBP mmHg	10 (7.00)	101022 10 2	2.51	0.473
80 103 (02.12) 11.551530 80-90 231 (45.38) 14.29±3.34 90-100 80 (15.72) 15.51±3.12 ≥100 33 (6.48) 11.84±8.87 WHR 1.91 0.167 <0.9 (male), 0.8 (female)	<80	165 (32 42)	12 30+5 36	2.01	0.175
90-100 80 (15.72) 15.51±3.12 ≥100 33 (6.48) 11.84±8.87 WHR 1.91 0.167 <0.9 (male), 0.8 (female)	80-90	231 (45 38)	14 29+3 34		
≥100 33 (6.48) 11.84±8.87 WHR 1.91 0.167 <0.9 (male), 0.8 (female)	90-100	80 (15 72)	1551+312		
WHR 1.91 0.167 <0.9 (male), 0.8 (female)	>100	33 (6.4.8)	11 84+8 87		
 <0.9 (male), 0.8 (female) ≥0.9 (male), 0.8 (female) 406 (79.76) 14.17±4.36 	WHR	0.10/	11.0 F±0.07	1 91	0.167
$\geq 0.9 \text{ (male)}, 0.8 \text{ (female)} 406 (79.76) 14.17\pm4.36$	<0.9 (male) 0.8 (female)	103 (20.24)	1166+371	1./1	0.107
	≥ 0.9 (male), 0.8 (female)	406 (79.76)	14.17±4.36		

BMI: Body mass index; Glu: Glucose; UA: Uric acid; TC: Serum total cholesterol; LDL: Low-density lipoprotein; WHR: Waist-to-hip ratio; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; TG: Triglyceride; Hcy: Homocysteine; MTHFR: Methylenetetrahydrofolate reductase

levels and environmental factors. We recruited 164 patients with both hypertension and IS (cases) and 345 patients with hypertension without IS (controls). We found that high levels of *MTHFR* promoter methylation reduced the risk of IS

Shan Xu, et al. A matched case-control study

TABLE 4. Regressior	n analysis of the	association between	environmental	factors and IS
---------------------	-------------------	---------------------	---------------	----------------

	Univariate an	alysis	Multivariate analysis		
Factor	OR (95%CI)	<i>p</i> -value	OR (95%CI)	<i>p</i> -value	
Gender					
Male	1.00	-	1.00	-	
Female	1.00 (0.69–1.45)	0.99	0.83 (0.47-1.46)	0.52	
Age, year					
<60	1.00	-	1.00	-	
60-70	0.97 (0.58-1.65)	0.92	0.73 (0.38-1.41)	0.34	
>70	0.90(0.53-1.55)	0.71	0.63(0.31-1.27)	0.20	
Smoking	0.50 (0.55 1.55)	0.71	0.00 (0.01 1.27)	0.20	
No	1.00		1.00		
Vec	1.23 (0.68-2.19)	0.49	1.64 (0.74-3.59)	0.22	
Passive smoking	1.25 (0.00-2.17)	0.49	1.04 (0.74-3.37)	0.22	
No.	1.00		1.00		
NO	1.00	- 0.47	0.77(0.41, 1.41)	- 0.40	
ies Otherstein a/d	0.85 (0.50-1.55)	0.47	0.77 (0.41–1.41)	0.40	
Oli intake, g/d	1.00		1.00		
<25	1.00	-	1.00	-	
25-40	1.04 (0.66–1.68)	0.87	1.61 (0.82–3.21)	0.17	
>40	0.68 (0.30–1.44)	0.32	1.10 (0.38–3.08)	0.86	
Salt intake, g/d					
≤6	1.00	-	1.00	-	
6–13	0.68 (0.45-1.05)	0.08	0.62 (0.34-1.16)	0.14	
>13	1.21 (0.60–2.43)	0.59	1.12 (0.44–2.83)	0.81	
Vegetable, g/d					
<300	1.00	-	1.00	-	
300-500	0.91 (0.44-1.95)	0.80	0.95 (0.40-2.33)	0.90	
>500	0.90 (0.41-2.02)	0.79	0.99 (0.40-2.56)	0.98	
Sleep status					
Bad	1.00	-	1.00	-	
Fairly good	0.69 (0.45-1.05)	0.08	0.80 (0.47-1.36)	0.42	
Good	0.98 (0.60-1.61)	0.95	1.11 (0.59-2.09)	0.74	
Depression					
No	1.00	-	1.00	-	
Yes	1.76 (1.18-2.63)	0.01	1.89 (1.14-3.17)	0.01	
Alcohol consumption	· · · · · · · · · · · · · · · · · · ·				
No	1.00	_	1.00	-	
Yes	0.49(0.29-0.79)	0.00	0.37 (0.20-0.69)	0.00	
I DL_mmol/L	0.19 (0.29 0.19)	0.00	0.57 (0.20 0.07)	0.00	
<361	1.00		1.00		
>2.61	0.81(0.50, 1.28)	0.37	1.22 (0.60, 2.46)	0.58	
	0.01 (0.30-1.20)	0.57	1.22 (0.00-2.40)	0.56	
(A, µ110)/L	1.00		1.00		
<416 (male), <339 (lemale)	1.00	-	1.00	-	
2410 (male), 2559(lemale)	1.15 (0.77-1.65)	0.55	1.27 (0.79–2.03)	0.52	
1G, mmol/ L	1.00		1.00		
0.34-2.26	1.00	-	1.00	-	
≥2.26	0.76 (0.48–1.19)	0.24	0.65 (0.37-1.12)	0.12	
Glu, mmol/L					
<6.1	1.00	-	1.00	-	
≥6.1	1.14 (0.74–1.75)	0.55	1.22 (0.72–2.07)	0.45	
BMI, kg/m ²					
<24	1.00	-	1.00	-	
24-28	0.94 (0.63–1.39)	0.76	1.04 (0.64–1.70)	0.86	
≥28	0.86 (0.45-1.59)	0.63	0.76 (0.34–1.65)	0.50	
TC, mmol/L					
<6.2	1.00	-	1.00	-	
≥6.2	0.86 (0.48-1.48)	0.59	0.81 (0.35-1.84)	0.61	
SBP, mmHg					
<120	1.00	-	1.00	-	
120-140	0.81 (0.42-1.59)	0.52	0.95 (0.43-2.15)	0.90	

(Contd...)

TABLE 4. (Continued)

	Univariate an	Univariate analysis		Multivariate analysis		
Factor	OR (95%CI)	<i>p</i> -value	OR (95%CI)	<i>p</i> -value		
140-160	0.73 (0.36–1.53)	0.40	0.82 (0.34-1.98)	0.66		
≥160	0.81 (0.32-2.01)	0.65	0.79 (0.25-2.41)	0.68		
DBP, mmHg						
<80	1.00	-	1.00	-		
80–90	0.89 (0.58-1.36)	0.58	0.82 (0.49-1.37)	0.45		
90-100	0.91 (0.51-1.60)	0.74	0.97 (0.47-2.01)	0.94		
≥100	1.30 (0.59–2.78)	0.50	1.16 (0.40-3.23)	0.78		
WHR						
<0.9 (man), 0.8 (women)	1.00	-	1.00	-		
≥0.9 (man), 0.8 (women)	0.90 (0.58-1.44)	0.67	1.13 (0.62-2.1)	0.69		
MTHFR						
Q1:P0-P25	1.00	-	1.00	-		
Q2:P25-P50	0.30 (0.18-0.50)	0.00	0.27 (0.15-0.47)	0.00		
Q3:P50-P75	0.07 (0.04-0.13)	0.00	0.07 (0.03-0.13)	0.00		
Q4:P75-P100	0.15 (0.08-0.25)	0.00	0.14 (0.07-0.25)	0.00		

BMI: Body mass index; Glu: Glucose; UA: Uric acid; TC: Serum total cholesterol; LDL: Low-density lipoprotein; WHR: Waist-to-hip ratio; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; TG: Triglyceride; MTHFR: Methylenetetrahydrofolate reductase; IS: Ischemic stroke

	OR (95% CI) of the MTHFR methylation level				
	Q ₁ (lowest)	Q ₂	Q ₃	Q4 (highest)	<i>p</i> -trend ^s
Male					
Control/case	26/46	29/23	65/8	59/8	
M0	1.00	0.45 (0.21-0.92)	0.07 (0.03-0.16)	0.08 (0.03-0.18)	< 0.001
M1	1.00	0.45 (0.21-0.93)	0.07 (0.03-0.16)	0.08 (0.03-0.17)	< 0.001
M2	1.00	0.42 (0.19-0.90)	0.07 (0.03-0.17)	0.07 (0.03-0.16)	< 0.001
M3	1.00	0.40 (0.17-0.88)	0.07 (0.02-0.16)	0.07 (0.02-0.16)	< 0.001
Female					
Control/case	20/34	55/21	48/6	43/18	
M0	1.00	0.22 (0.10-0.47)	0.07 (0.02-0.19)	0.25 (0.11-0.53)	0.160
M1	1.00	0.23 (0.11-0.48)	0.06 (0.02-0.17)	0.25 (0.11-0.53)	0.167
M2	1.00	0.20 (0.08-0.43)	0.06 (0.02-0.17)	0.28 (0.12-0.63)	0.432
M3	1.00	0.17 (0.07-0.38)	0.06 (0.02-0.16)	0.23 (0.09-0.54)	0.260
Total					
Control/case	46/80	84/44	113/14	102/26	
M0	1.00	0.30 (0.18-0.50)	0.07 (0.04-0.13)	0.15 (0.08-0.25)	< 0.001
M1	1.00	0.30 (0.18-0.51)	0.07 (0.03-0.13)	0.14 (0.08-0.25)	< 0.001
M2	1.00	0.28 (0.16-0.47)	0.07 (0.03-0.14)	0.14 (0.08-0.25)	< 0.001
M3	1.00	0.27 (0.16-0.47)	0.07 (0.03-0.14)	0.13 (0.07-0.24)	< 0.001

a. Model M_0 : Unadjusted model. M1 adjusted for age and gender. M2 adjusted for smoking, BMI, WHR, depression, sleep, and oil and salt intake on the basis of model M_1 . On the basis of model M_2 , factors such as SBP, Glu, TC, TG, LDL, and Hcy were further corrected in model M_3 . b. Quartile was coded as 1, 2, 3, and 4. BMI: Body mass index; Glu: Glucose; TC: Serum total cholesterol; LDL: Low-density lipoprotein; WHR: Waist-to-hip ratio; SBP: Systolic blood pressure; TG: Triglyceride; MTHFR: Methylenetetrahydrofolate reductase; IS: Ischemic stroke; Hcy: Homocysteine

in patients with hypertension by 86% compared with those with low levels of *MTHFR* promoter methylation, after adjusting for potential confounders. Increased *MTHFR* promoter methylation levels had a stronger protective effect on IS risk in men than in women.

IS is a complex neurological disease caused by both genetic and environmental factors [24]. DNA methylation profiles have been associated with many of the pathological changes that accompany aging. DNA methylation plays an important role in regulating gene expression and has the potential to modulate IS risk [25]. A previous study that performed a luminometric methylation assay found no correlation between total DNA methylation levels and IS [26]. Another study found that total DNA hypomethylation increased the risk of IS [27]. Here, we found that high levels of *MTHFR* promoter methylation reduced IS risk in patients with hypertension.

MTHFR encodes one of the enzymes required for the metabolism of Hcy – a previously reported independent risk factor for IS [24]. Folic acid also antagonizes HHcy formation during Hcy metabolism [28]. Nagele et al. [22] found that extensive folic acid fortification in the population could significantly reduce Hcy plasma levels and possibly reduce the role

Eastor	OR (95% CI) of the MTHFR methylation level (case vs. control)					nintoraction
ractor	Q ₁	Q_2	Q_3	Q_4	<i>p</i> -trend	<i>p</i> interaction
Age, year						0.163
<60	1.00	0.52 (0.11-2.29)	0.03 (0.00-0.13)	0.03 (0.00-0.14)	0.001	
60-70	1.00	0.28 (0.13-0.60)	0.09 (0.03-0.24)	0.18 (0.08-0.40)	0.002	
≥70	1.00	0.25 (0.11-0.57)	0.07 (0.02-0.20)	0.20 (0.08-0.47)	0.013	
Gender						0.024
Male	1.00	0.45 (0.21-0.92)	0.07 (0.03-0.16)	0.08 (0.03-0.18)	< 0.001	
Female	1.00	0.22 (0.10-0.47)	0.07 (0.02-0.19)	0.25 (0.11-0.53)	0.061	
Depression						0.933
No	1.00	0.28 (0.15-0.53)	0.08 (0.03-0.17)	0.15 (0.08-0.30)	< 0.001	
Yes	1.00	0.30 (0.11-0.74)	0.05 (0.01-0.18)	0.12 (0.04-0.34)	0.001	
Sleep status						0.456
Bad	1.00	0.33 (0.14-0.75)	0.03 (0.00-0.10)	0.11 (0.04-0.29)	< 0.001	
Fairly good	1.00	0.29 (0.12-0.65)	0.06 (0.02-0.18)	0.16 (0.07-0.37)	0.003	
Good	1.00	0.28 (0.09-0.85)	0.18 (0.05-0.61)	0.19 (0.05-0.64)	0.077	
Hcy, μmol/L						0.295
<15	1.00	0.36 (0.17-0.74)	0.12 (0.05-0.26)	0.22 (0.10-0.44)	0.003	
≥15	1.00	0.26 (0.13-0.53)	0.04 (0.01-0.11)	0.09 (0.03-0.21)	< 0.001	
Glu, mmol/ L						0.356
<6.1	1.00	0.36 (0.20-0.64)	0.07 (0.03-0.14)	0.14 (0.07-0.26)	< 0.001	
≥6.1	1.00	0.14 (0.04–0.44)	0.08 (0.02-0.27)	0.17 (0.06-0.47)	0.023	

TABLE 6. The effects of the interaction between MTHFR methylation level and environmental factors on IS

MTHFR: Methylenetetrahydrofolate reductase; Hcy: Homocysteine; IS: Ischemic stroke; Glu: Glucose



FIGURE 1. A receiver operating characteristic curve showing that methylenetetrahydrofolate reductase (*MTHFR*) promoter methylation levels could predict ischemic stroke.

of the *MTHFR* C677T polymorphism in increasing plasma Hcy levels. Wei et al. [29] found that *MTHFR* promoter methylation profiles at CpG islet A were associated with the serum levels of folate and vitamin B12 – the coenzymes involved in one-carbon metabolism, and that one-carbon metabolism has an important role in modulating DNA methylation. Vitamin B12 or folate can reduce S-adenosylmethionine bioavailability, which hinders genome-wide methylation and, specifically, lysine 4 histone H3 trimethylation (H3K4me3). Moreover, a low level of H3K4me3 might affect *MTHFR* transcriptional activity [29].

We found that the protective effect of MTHFR hypermethylation on IS was more pronounced in men. Sebag et al. [30] found that in both male and female mice, DNA methylation patterns were associated with the stability of DNA sequences and that life events had notable effects on DNA methylation in somatic cells. A possible explanation for this phenomenon is the effects of sex hormones on DNA methylation. They also found differential CpG methylation at the CSQ2 promoter between male and female mice and concluded that sex hormones are necessary to maintain the DNA methylation patterns at this locus. However, the extent to which DNA methylation at specific sites in humans is affected by sex, genetic and environmental factors needs further study. We found no difference between the ROC curves that were adjusted or not for potential confounders (age, sex, etc.). This finding implies that MTHFR promoter methylation has a consistent, significant effect on IS risk.

A strength of our study is its analysis of a cohort of participants that share a similar genetic background and have established health records in community health service centers. We collected the data conforming to rigid quality controls, using a questionnaire that was verified to be reliable. Some limitations to this study should, however, be noted. The inherent nature of this case–control, retrospective study means that it cannot provide direct causal associations. In addition, recall bias might have affected the results, as the data on lifestyle were self-reported. The frequency of vegetable intake was also self-reported; as such, we could not calculate the specific consumption of B6, B12 and folic acid, which might be potential confounders.

CONCLUSION

We showed that high levels of *MTHFR* promoter methylation are protective against IS in patients with hypertension. Only sex and *MTHFR* promoter methylation levels showed interaction effects on IS. These data support the potential application of *MTHFR* promoter methylation status as a predictive biomarker for IS, pending future confirmatory studies.

ACKNOWLEDGMENTS

The research was supported by grants from the National Natural Science Foundation of China (81803316), Guangdong Province Medical Science and Technology Research Foundation (A2019421), Shenzhen Science and Technology Innovation Committee (JCYJ20170307100942297), and Shenzhen Health and Family Planning Commission (SZBC2017005).

REFERENCES

- O'Donnell MJ, Chin SL, Rangarajan S, Xavier D, Liu L, Zhang H, et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): A case-control study. Lancet 2016;388(10046):761-75 https://doi.org/10.1016/S0140-6736(16)30506-2.
- [2] Feigin VL, Mensah GA, Norrving B, Murray CJ, Roth GA, GBD 2013 Stroke Panel Experts Group. Atlas of the global burden of stroke (1990-2013): The GBD 2013 study. Neuroepidemiology 2015;45(3):230-6.

https://doi.org/10.1159/000441106.

- Paul SL, Srikanth VK, Thrift AG. The large and growing burden of stroke. Curr Drug Targets 2007;8(7):786-93 https://doi.org/10.2174/138945007781077418.
- [4] Wang W, Jiang B, Sun H, Ru X, Sun D, Wang L, et al. Prevalence, incidence, and mortality of stroke in China: Results from a nationwide population-based survey of 480 687 adults. Circulation 2017;135(8):759-71.

https://doi.org/10.1161/circulationaha.116.025250.

[5] Satyaki PR, Gehring M. DNA methylation and imprinting in plants: Machinery and mechanisms. Crit Rev Biochem Mol Biol 2017;52(2):163-75.

https://doi.org/10.1080/10409238.2017.1279119.

- [6] Bressler J, Shimmin LC, Boerwinkle E, Hixson JE. Global DNA methylation and risk of subclinical atherosclerosis in young adults: The Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study. Atherosclerosis 2011;219(2):958-62 https://doi.org/10.1016/j.atherosclerosis.2011.09.040.
- [7] Chiarella J, Tremblay RE, Szyf M, Provençal N, Booij L. Impact of early environment on children's mental health: Lessons from DNA methylation studies with monozygotic twins. Twin Res Hum Genet 2015;18(6):623-34.

https://doi.org/10.1017/thg.2015.84.

- [8] Toperoff G, Aran D, Kark JD, Rosenberg M, Dubnikov T, Nissan B, et al. Genome-wide survey reveals predisposing diabetes Type 2-related DNA methylation variations in human peripheral blood. Hum Mol Genet 2012;21(2):371-83. https://doi.org/10.1093/hmg/ddr472.
- Szyf, M. The early-life social environment and DNA methylation. Clin Genet 2012;81(4):341-9 https://doi.org/10.1111/j.1399-0004.2012.01843.x.
- [10] Needham BL, Smith JA, Zhao W, Wang X, Mukherjee B, Kardia SL,

et al. Life course socioeconomic status and DNA methylation in genes related to stress reactivity and inflammation: The multi-ethnic study of atherosclerosis. Epigenetics 2015;10(10):958-69. https://doi.org/10.1080/15592294.2015.1085139.

- [11] Pei F, Wang X, Yue R, Chen C, Huang J, Huang J, et al. Differential expression and DNA methylation of angiotensin Type 1A receptors in vascular tissues during genetic hypertension development. Mol Cell Biochem 2015;402(1-2):1-8 https://doi.org/10.1007/\$11010-014-2295-9.
- [12] Serra-Juhé C, Cuscó I, Homs A, Flores R, Torán N, Pérez-Jurado LA. DNA methylation abnormalities in congenital heart disease. Epigenetics 2015;10(2):167-77. https://doi.org/10.1080/15592294.2014.998536.
- [13] Baccarelli A, Wright R, Bollati V, Litonjua A, Zanobetti A, Tarantini L, et al. Ischemic heart disease and stroke in relation to blood DNA methylation. Epidemiology 2010;21(6):819-28. https://doi.org/10.1097/ede.ob013e3181f20457.
- [14] Han L, Wu Q, Wang C, Hao Y, Zhao J, Zhao J, Zhang L, et al. Homocysteine, ischemic stroke, and coronary heart disease in hypertensive patients: A population-based, prospective cohort study. Stroke 2015;46(7):1777-86.

https://doi.org/10.1161/strokeaha.115.009111.

- [15] Wang CY, Chen ZW, Zhang T, Liu J, Chen SH, Liu SY, et al. Elevated plasma homocysteine level is associated with ischemic stroke in Chinese hypertensive patients. Eur J Intern Med 2014;25(6):538-44. https://doi.org/10.1016/j.ejim.2014.04.011.
- [16] Towfighi A, Markovic D, Ovbiagele B. Pronounced association of elevated serum homocysteine with stroke in subgroups of individuals: A nationwide study. J Neurol Sci 2010;298(1-2):153-7. https://doi.org/10.1016/j.jns.2010.07.013.
- [17] Luo X, Luo Z, Zhang Z, Yang H, Lai B, Yao Q, et al. Homocysteine upregulates hepcidin expression through BMP6/SMAD signaling pathway in hepatocytes. Biochem Biophys Res Commun 2016;471(2):303-8.

https://doi.org/10.1016/j.bbrc.2016.02.001.

- [18] Coşar A, Ipçioğlu OM, Ozcan O, Gültepe M. Folate and homocysteine metabolisms and their roles in the biochemical basis of neuropsychiatry. Turk J Med Sci 2014;44(1):1-9. https://doi.org/10.3906/sag-1211-39.
- [19] Binia A, Contreras AV, Canizales-Quinteros S, Alonzo VA, Tejero ME, Silva-Zolezzi I. Geographical and ethnic distribution of single nucleotide polymorphisms within genes of the folate/homocysteine pathway metabolism. Genes Nutr 2014;9(5):421. https://doi.org/10.1007/s12263-014-0421-7.
- [20] Lv QQ, Lu J, Sun H, Zhang JS. Association of methylenetetrahydrofolate reductase (MTHFR) gene polymorphism with ischemic stroke in the Eastern Chinese Han population. Genet Mol Res 2015;14(2):4161-8. https://doi.org/10.4238/2015.april.27.31.

[21] Wang C, Xu G, Wen Q, Peng X, Chen H, Zhang J, et al. CBS promoter hypermethylation increases the risk of hypertension and stroke. Clinics (Sao Paulo) 2019;74:e630.

- https://doi.org/10.6061/clinics/2019/e630.
- [22] Nagele P, Meissner K, Francis A, Födinger M, Saccone NL. Genetic and environmental determinants of plasma total homocysteine levels: Impact of population-wide folate fortification. Pharmacogenet Genomics 2011;21(7):426-31. https://doi.org/10.1097/fpc.ob013e32834741ff.
- [23] Knight RG, Waal-Manning HJ, Spears GF. Some norms and rel2ability data for the state-trait anxiety inventory and the Zung self-rating depression scale. Br J Clin Psychol 1983;22(Pt 4):245-9. https://doi.org/10.1111/j.2044-8260.1983.tb00610.x.
- [24] He Y, Li Y, Chen Y, Feng L, Nie Z. Homocysteine level and risk of different stroke types: A meta-analysis of prospective observational studies. Nutr Metab Cardiovasc Dis 2014;24(11):1158-65. https://doi.org/10.1016/j.numecd.2014.05.011.
- [25] Gravina GL, Festuccia C, Marampon F, Popov VM, Pestell RG, Zani BM, et al. Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation. Mol Cancer 2010;9:305.

https://doi.org/10.1186/1476-4598-9-305.

- [26] Soriano-Tárraga C, Jiménez-Conde J, Giralt-Steinhauer E, Mola M, Ois A, Rodríguez-Campello A, et al. Global DNA methylation of ischemic stroke subtypes. PLoS One 2014;9(4):e96543. https://doi.org/10.1371/journal.pone.0096543.
- [27] Baccarelli A, Wright R, Bollati V, Litonjua A, Zanobetti A, Tarantini L, et al. Ischemic heart disease and stroke in relation to blood DNA methylation. Epidemiology 2010;21(6):819-28. https://doi.org/10.1097/ede.ob013e3181f20457.
- [28] Ma Y, Peng D, Liu C, Huang C, Luo J. Serum high concentrations of homocysteine and low levels of folic acid and Vitamin B12, are significantly correlated with the categories of coronary artery diseases. BMC Cardiovasc Disord 2017;17(1):37.

Related articles published in BJBMS

- 1. DNA methylation of AHCY may increase the risk of ischemic stroke Lei Zhao et al., BJBMS, 2020
- 2. Elevation in circulating YKL-40 concentration in patients with cerebrovascular disease Xue Xu et al., BJBMS, 2014

https://doi.org/10.1186/s12872-017-0475-8.

[29] Wei LK, Sutherland H, Au A, Camilleri E, Haupt LM, Gan SH, et al. A potential epigenetic marker mediating serum folate and Vitamin B12 levels contributes to the risk of ischemic stroke. Biomed Res Int 2015;2015:167976.

https://doi.org/10.1155/2015/167976.

[30] Sebag IA, Gillis MA, Calderone A, Kasneci A, Meilleur M, Haddad R, et al. Sex hormone control of left ventricular structure/ function: Mechanistic insights using echocardiography, expression, and DNA methylation analyses in adult mice. Am J Physiol Heart Circ Physiol 2011;301(4):H1706-15. https://doi.org/10.1152/ajpheart.00088.2011.